UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector

Cancer discovery, 2019-10, Vol.9 (10), p.1422-1437

2019

Volltextzugriff (PDF)

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo -Expanded Autologous NK Cells

Clinical cancer research, 2018-08, Vol.24 (16), p.4006-4017

2018

Volltextzugriff (PDF)

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Blood, 2010-09, Vol.116 (13), p.2286-2294

2010

Volltextzugriff (PDF)

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Blood, 2017-06, Vol.129 (25), p.3294-3303

2017

Volltextzugriff (PDF)

TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma

Haematologica (Roma), 2024-02, Vol.109 (2), p.578-590

2024

Volltextzugriff (PDF)

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Cancer Immunology, Immunotherapy, 2013-12, Vol.62 (12), p.1841-1849

2013

Volltextzugriff (PDF)

The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells

Nature immunology, 2019-01, Vol.20 (1), p.10-17

2019

Volltextzugriff (PDF)

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Blood, 2011-12, Vol.118 (24), p.6387-6391

2011

Volltextzugriff (PDF)

The role of natural killer cells in immunity against multiple myeloma

Leukemia & lymphoma, 2012-09, Vol.53 (9), p.1666-1676

2012

Volltextzugriff (PDF)

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

Clinical cancer research, 2015-09, Vol.21 (18), p.4055-4061

2015

Volltextzugriff (PDF)

A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells

International journal of cancer, 2012-03, Vol.130 (6), p.1459-1469

2012

Volltextzugriff (PDF)

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

Journal of clinical oncology, 2012-06, Vol.30 (16), p.1960-1965

2012

Volltextzugriff (PDF)

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Blood, 2012-11, Vol.120 (22), p.4324-4333

2012

Volltextzugriff (PDF)

The Transcription Factor AHR Prevents the Differentiation of a Stage 3 Innate Lymphoid Cell Subset to Natural Killer Cells

Cell reports (Cambridge), 2014-07, Vol.8 (1), p.150-162

2014

Volltextzugriff (PDF)

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers

Journal of proteomics, 2016-03, Vol.136, p.89-98

2016

Volltextzugriff (PDF)

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Blood, 2009-09, Vol.114 (13), p.2667-2677

2009

Volltextzugriff (PDF)

Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function

JCI insight, 2021-03, Vol.6 (6)

2021

Volltextzugriff (PDF)

Checkpoint inhibition in myeloma

Hematology, 2016-12, Vol.2016 (1), p.528-533

Benson, Jr, Don M

2016

Volltextzugriff (PDF)

Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma

Leukemia & lymphoma, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-7

2023

Volltextzugriff (PDF)

The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity

Molecular cancer, 2010-06, Vol.9 (1), p.165-165, Article 165

2010

Volltextzugriff (PDF)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients

Frontiers in oncology, 2021-02, Vol.10, p.575168-575168

2021

Volltextzugriff (PDF)

Killer Immunoglobulin-like Receptors and Tumor Immunity

Cancer immunology research, 2014-02, Vol.2 (2), p.99-104

2014

Volltextzugriff (PDF)

A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma

Cancer immunology research, 2018-07, Vol.6 (7), p.776-787

2018

Volltextzugriff (PDF)

Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant

Frontiers in oncology, 2022-02, Vol.12, p.801879-801879

2022

Volltextzugriff (PDF)

Pro- and Antiinflammatory Cytokine Signaling: Reciprocal Antagonism Regulates Interferon-gamma Production by Human Natural Killer Cells

Immunity (Cambridge, Mass.), 2006-05, Vol.24 (5), p.575-590

2006

Volltextzugriff (PDF)

1 – 25 von 358

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(298)
Mit Volltextzugriff
(307)

Publikationsform

Sprache

Englisch
(358)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector

Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo -Expanded Autologous NK Cells

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

The role of natural killer cells in immunity against multiple myeloma

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

The Transcription Factor AHR Prevents the Differentiation of a Stage 3 Innate Lymphoid Cell Subset to Natural Killer Cells

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function

Checkpoint inhibition in myeloma

Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma

The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients

Killer Immunoglobulin-like Receptors and Tumor Immunity

A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma

Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant

Pro- and Antiinflammatory Cytokine Signaling: Reciprocal Antagonism Regulates Interferon-gamma Production by Human Natural Killer Cells

Suchergebnisse filtern